Showing results (131-140 of 175) with videos related to
Sort By:
Pageof 18
Clinical Lung Cancer|August 11, 2016
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403Naohiro Oda, Eiki Ichihara, Katsuyuki Hotta, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2015
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001Eiki Ichihara, Katsuyuki Hotta, Naoyuki Nogami, et al.International Journal of Cancer|January 10, 2024
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancerAyako Morita, Eiki Ichihara, Koji Inoue, et al.Molecular Oncology|May 22, 2026
Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr-mutated lung cancerJun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, et al.Lung Cancer (Amsterdam, Netherlands)|May 7, 2026
Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion)Hiroyasu Kaneda, Motoko Tachihara, Yukihiro Toi, et al.Cancer Science|September 15, 2023
Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancerChihiro Ando, Eiki Ichihara, Tatsuya Nishi, et al.Clinical Lung Cancer|July 14, 2016
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405)Hideko Isozaki, Katsuyuki Hotta, Eiki Ichihara, et al.Asia-Pacific Journal of Clinical Oncology|September 5, 2020
Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trialGo Makimoto, Katsuyuki Hotta, Isao Oze, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 3, 2019
Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation BurdenGo Makimoto, Kadoaki Ohashi, Shuta Tomida, et al.Lung Cancer (Amsterdam, Netherlands)|April 21, 2026
Immune-related gene expression profiling and alectinib efficacy for patients with ALK-Rearranged non-small cell lung cancer: exploratory analysis of a prospective observational studyTakashi Kurosaki, Shinichiro Suzuki, Yasutaka Watanabe, et al.Pageof 18